menu search

Aim immunotech selected to present at the 3rd annual marie sklodowska-curie symposium on cancer research and care

OCALA, Fla., Sept. 22, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAlee...

September 22, 2023, 9:05 am

Aim immunotech to present at the h.c. wainwright 25th annual global investment conference

OCALA, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas...

September 5, 2023, 9:05 am

Aim immunotech to discuss second quarter 2023 financial results on august 15, 2023, and host conference call and webcast

OCALA, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that managem...

August 9, 2023, 1:05 pm

Aim immunotech to discuss second quarter 2023 financial results on august 15, 2023, and host conference call and webcast

OCALA, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that manageme...

August 9, 2023, 9:05 am

Aim immunotech announces completion of enrollment in phase 2 study evaluating ampligen® for the treatment of post-covid conditions

Topline data expected as early as Q1 2024 OCALA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today a...

August 8, 2023, 12:05 pm

Aim immunotech issues notice that an unaffiliated third party and organization are providing false information related to relationship with company and its affiliates

OCALA, Fla., July 18, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a notice that t...

July 18, 2023, 11:30 pm

Aim immunotech announces publication of positive findings from a pre-clinical study evaluating ampligen® in the treatment of pancreatic cancer in the american journal of cancer research

Findings support efforts in ongoing Early Access Program and upcoming clinical trials, and suggest Ampligen’s potential to reduce tumor cell growth ...

June 27, 2023, 3:16 pm

Aim immunotech to participate in the healthcare virtual conference presented by maxim group llc and hosted by m-vest

OCALA, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company fo...

June 14, 2023, 8:45 am

Aim immunotech to discuss first quarter 2023 financial results on may 16, 2023 and host conference call and webcast

OCALA, Fla., May 09, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company foc...

May 9, 2023, 12:50 pm

Police dogs catch man who stole refrigerated semi-truck with more than gbp 150,000 worth of food in ocala, fl, usa

The truck contained fresh seafood and meats worth over USD 200,000 [GBP 159,850]. Marti-Rosell was charged with multiple offences, including grand the...

April 13, 2023, 3:29 pm

Aim immunotech to report full year 2022 financial results on march 31, 2023 and host inaugural quarterly conference call and webcast

OCALA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company fo...

March 27, 2023, 9:05 am

Aim immunotech announces phase 2 study of ampligen® for the treatment of pancreatic cancer is open and recruiting patients

Ongoing efforts to open additional clinical sites for recruitment at premier cancer centers across the U.S. and Europe are in progress to facilitate p...

February 28, 2023, 1:45 pm

Aim immunotech says cash position expected to fund operations through end of 2023

AIM ImmunoTech Inc (NYSE:AIM) said it ended the third quarter of 2022 with cash and cash equivalents of $36.7 million, down from $48.3 million at the...

November 15, 2022, 9:32 am

Aim immunotech to present at the h.c. wainwright 24th annual global investment conference

OCALA, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company fo...

September 7, 2022, 7:25 am

Aim immunotech boosts intellectual property with new netherlands utility patent covering ampligen and dsrna products aimed at covid-19

AIM ImmunoTech Inc (NYSE:AIM) revealed that the Netherlands Patent Office (Octrooicentrum Nederland) has issued Patent No 2027383 - a utility patent ...

June 13, 2022, 10:02 am

Planet 13 holdings announces third florida dispensary located in ocala

Planet 13 Holdings Inc (CSE:PLTH, OTCQX:PLNHF) has announced the third location of its planned Florida dispensary network based in the city of Ocala....

June 9, 2022, 7:23 am

Aim immunotech reports positive data from phase 2a study evaluating ampligen as part of a regimen treating colorectal cancer that has spread to the liver

AIM ImmunoTech Inc (NYSE:AIM) presented positive data from its ongoing Phase 2a clinical study at the Roswell Park Comprehensive Cancer Center evalua...

April 11, 2022, 11:47 am

Aim immunotech wins ind clearance from fda to proceed with phase 2 study of ampligen for treating locally advanced pancreatic cancer

AIM ImmunoTech Inc (NYSE:AIM) revealed that it has received a notification from the US Food and Drug Administration (FDA) stating that the clinical ho...

March 16, 2022, 9:15 am


Search within

Pages Search Results: